Study: Atezolizumab Improves Survival in SCLC
- PMID: 30305284
- DOI: 10.1158/2159-8290.CD-NB2018-133
Study: Atezolizumab Improves Survival in SCLC
Abstract
Combining the PD-L1 inhibitor atezolizumab with platinum-based chemotherapy improves overall survival among patients with extensive-stage small cell lung cancer relative to chemotherapy alone. These findings could lead to a new first-line treatment option for patients with the disease.
©2018 American Association for Cancer Research.
Comment on
-
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials